How to Help Your Patients Save Money on Monovisc: A Provider's Guide to Savings Programs

For many patients with knee osteoarthritis, Monovisc offers a compelling clinical profile: a single high-dose HA injection, non-avian formulation, and up to 6 months of potential pain relief. But at a cash price of $1,521–$2,047 per syringe — plus administration fees — cost can be a real barrier to access. As a provider, your team is often the first line of defense in helping patients navigate the financial landscape. This guide walks through every cost-reduction pathway available for Monovisc in 2026.

Understanding the Cost Structure: Why Monovisc Is Expensive

Monovisc's cost reflects several factors: it is a brand-only specialty product (no generic equivalent as of 2026), it uses proprietary cross-linking technology developed by Anika Therapeutics, and its distribution through specialty medical channels carries higher overhead than the retail pharmacy supply chain. The absence of generic competition means pricing has remained high, and insurance formulary pressures have increased as well.

For providers, understanding the cost breakdown helps you advise patients accurately:

Product cost only: $1,521–$2,047 per syringe

Total procedure (product + administration fee): $955–$2,291 depending on provider, location, and whether imaging guidance is used

With prior-authorized commercial insurance: Estimated $100–$350 patient copay/coinsurance

Medicare Part B: 20% coinsurance after Part B deductible (~$300–$400 if deductible met, $0 if supplemental coverage)

Pathway 1: Maximize Medicare Part B Coverage

For patients with Medicare, Monovisc is covered under Part B as a physician-administered medical device using J-code J7327. Medicare provides the strongest coverage pathway for Monovisc, often with no prior authorization required. To maximize coverage:

Ensure robust chart documentation of knee OA diagnosis (ICD-10 M17), failed conservative treatment history, and medical necessity — this protects against retrospective audit denials

Verify that X-ray imaging within the past 12 months is in the chart — most MACs expect imaging support

Advise patients with Medigap supplement plans to check whether their plan covers the 20% coinsurance — many do, which would make Monovisc effectively no-cost beyond the deductible

For Medicare Advantage patients, verify specific plan coverage — MA plans can have different cost-sharing and prior authorization requirements than traditional Medicare

Pathway 2: Prior Authorization Strategy for Commercial Plans

For commercial insurance patients, the prior authorization process is the critical cost-access gateway. In 2026, Aetna and many BCBS plans classify Monovisc as non-preferred, requiring PA and potentially step therapy. Here's how to optimize PA success rates in your practice:

Submit day-of-prescription: Initiate the PA request the same day you prescribe Monovisc — don't wait for the patient to ask about it

Use electronic prior authorization: Platforms like CoverMyMeds, Availity, or Epic PA management can significantly reduce processing time versus phone/fax PA

Build a strong clinical narrative: For non-preferred status plans, include a letter of medical necessity explaining specifically why Monovisc is the appropriate choice (avian allergy precluding Synvisc-One, preference for maximum-dose single injection, patient's prior positive response to Monovisc)

Appeal denials promptly: Request denial reasoning in writing; file appeal within the plan's timeframe (typically 30–60 days); appeals with strong documentation have meaningful success rates

Pathway 3: Johnson & Johnson Patient Assistance Program

For uninsured or underinsured patients, the Johnson & Johnson Patient Assistance Foundation offers a program that may provide Monovisc at no charge to eligible patients. Eligibility is typically income-based and requires the patient to lack adequate insurance coverage for the medication. Your office staff can help facilitate the application process:

Direct the patient to pparx.org (Partnership for Prescription Assistance) or the J&J Patient Assistance Foundation website

Your office will typically need to complete the provider section of the application form and provide diagnosis and prescription documentation

Processing typically takes 2–4 weeks; plan the patient's treatment timeline accordingly

Pathway 4: Discount Programs for Self-Pay Patients

For patients who will be paying out of pocket for Monovisc, prescription savings cards can reduce the cost at participating locations. GoodRx and SingleCare both show discounted prices — SingleCare as low as approximately $1,469. Patients should also consider:

HSA/FSA payment: Monovisc is a qualified medical expense eligible for HSA and FSA funds, effectively providing a 20–35% discount through pre-tax payment

MDsave upfront pricing: The MDsave platform offers bundled procedure pricing (product + administration) starting at $955; patients can purchase their procedure upfront at a discounted rate

Shop provider fees: Independent outpatient orthopedic clinics typically charge significantly less than hospital outpatient departments for the same procedure — advise cost-sensitive patients to compare provider fees, not just drug prices

Pathway 5: When to Recommend a Covered Alternative

If cost barriers cannot be overcome through the above pathways, a clinically comparable alternative with better insurance coverage may be the most practical solution for cost-sensitive patients. Key alternatives to consider:

Durolane or Synvisc-One — preferred single-injection alternatives on Aetna and many BCBS plans; no prior authorization required for preferred status

Euflexxa — preferred multi-injection alternative; strong Medicare and commercial coverage; non-avian formulation

For additional resources to help your patients navigate Monovisc access, visit medfinder for providers or read our comprehensive provider guide on Monovisc access in 2026.